Thursday 12 January 2023, 8:06 a.m.
The Genome Center gives good news. Two strains of booster vaccines reduce sickness and death with clear results.
January 12, 2023 Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital posted pictures and messages via Facebook Center for Medical Genomics notifying good news that the bivalent booster vaccine (bivalent-booster) can help reduce the rate of severe illness that requires hospitalization. nurse and significantly reduced mortality in those infected with the original Omicron strain and its sub-emergency substrains compared with those not receiving the two-strain booster vaccine.
The study is one of the first studies to evaluate the efficacy of a two-dose booster vaccine from more than 600,000 elderly (≥65 years) volunteers in Israel who received the booster version. Second generation, two-strain type, just “one dose” was found to prevent severe infection requiring hospitalization by 81% and reduce the mortality rate by 86% (by follow-up). booster vaccination following 70 days)
The results of this research are to be published in the Lancet journal, which is immediately accessible via the Internet, but is pending review by experts in the field.
This retrospective study gathered data from the Clalit Health Service in Israel with eight major hospitals during September-December 2022.
A total of 622,701 volunteers participated, of whom 85,314 or 14% met the criteria for the two-dose booster vaccine. (Containing original Wuhan virus and Omicron BA.4 and BA.5) 1 dose and followed up for another 70 days.
Only six people who received the booster vaccine and were infected with Omicron required hospitalization due to COVID-19, compared to those who did not receive the booster vaccine for two strains. A total of 276 people were admitted to the hospital (Photo 1).
Only one person was vaccinated with the double-dose booster and subsequently died due to COVID-19 infection compared to the number of deaths among those who were not vaccinated with the double-dose booster. to 73 people
These findings underscore the need for vulnerable groups (608), especially those over 65, to receive two-dose booster vaccination. (bivalent-booster)
In Israel during the storage period from 24 Sep. 2022 to 12 Dec. 2022, there was an outbreak of Omikron.
BA.2 had a 0.69% outbreak share.
BA.4 had a 2.69% share of the outbreak.
BA.5 has an outbreak share of 85.03%.
BA.2.75 has a 4.01% outbreak share.
BQ.1* had a 6.89% outbreak share.
XBB* has a 0.31% outbreak share and
Deltacron had a 0.38% outbreak share.
(Picture 2)
.jpg)
It is assumed that the two-strain booster vaccination can reduce both the morbidity and mortality rate from the original Omikron strain BA.2, BA.4, BA.5, and the emerging subspecies of omikron mutants BQ.1*, XBB*, and Deltakron.
Although emerging subspecies of omikrons such as BQ.1* and XBB* have so modulated the spike protein fraction that narrow spectrum antibodies produced by B-cells cannot recognize them, they bind and destroyable However, these subspecies of omikron are unable to escape the immune system from T-cells. regardless of which cell is infected with the virus (board spectrum) up to 85%
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4314067
https://www.scientificamerican.com/…/why-covids-xbb-1…/
-005
